Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2014 Apr 18;13(7):1826–1836. doi: 10.1158/1535-7163.MCT-13-1093

Fig. 5. The CM combination inhibits HNSCC xenograft tumor growth in vivo.

Fig. 5

Mice bearing subcutaneous SCC47 and Tu212 tumors of approximately 100 mm3 were treated by intraperitoneal injection (i.p.) twice per week for 4 weeks with: PBS (phosphate-buffered saline) control, cetuximab (6.25μg/dose), MM-121 at low dose (300μg/dose, MM-121.LD), MM-121 at high dose (600μg/dose, MM-121.HD), the combination with LD MM-121 (Comb.LD), and the combination with HD MM-121 (Comb.HD). A, tumor volumes were measured three times a week. B, tumors were harvested and weighed 26 (Tu212) and 29 (SCC47) days after the first treatment. C, major organs were harvested for toxicity evaluation by H&E (Magnification: 100×). Error bars are mean ± SE of 7 mice from each group. (** indicates p<0.01 v.s. Ctrl, † indicates p<0.05 v.s. cetuximab)